GANX Gain Therapeutics, Inc.
Price Chart
Executive Summary
Gain Therapeutics announced interim clinical and biomarker data from Part 2 of its Phase 1b study of GT-02287 in Parkinson's disease. Key positive findings include an 81% reduction in CSF GluSph in elevated-baseline patients and a 4.8-point difference in MDS-UPDRS scores favoring high-baseline patients at Day 150, with all 16 participants remaining on study. The data supports continued development toward a planned Phase 2 trial, but remains early-stage and open-label.
Actionable Insight
The data is encouraging but early; monitor for initiation of the Phase 2 trial and any partnership or funding announcements. Given the small sample size and open-label design, the stock may react positively in the near term, but sustained upside depends on confirmatory data.
Key Facts
- GT-02287 showed an 81% reduction in CSF GluSph after 90 days in participants with elevated baseline levels.
- At Day 150, a 4.8-point difference in MDS-UPDRS Part II+III scores favored high-baseline GluSph participants over low-baseline.
- All 16 participants from Part 1 continued into the 9-month extension and remain on study through Day 150.
- Perceived benefits included improved smell/taste, balance/gait, and sleep in a subset of participants.
- A Phase 2 trial is planned with endpoints including UPSIT and wearable sensor gait assessments.
Financial Impact
No financial data provided; pre-revenue clinical-stage biotech.
Risk Factors
- Phase 1b open-label trial with small sample size (n=16) limits statistical reliability.
- Future Phase 2 trial may not replicate results; high failure rate in Parkinson's disease trials.
- Company is pre-revenue with $76M market cap; financing risk if cash runway is insufficient.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-066062 |
| Document: 0001104659-26-066062-index-headers.html | 0001104659-26-066062 |
| Document: 0001104659-26-066062-index.html | 0001104659-26-066062 |
| Document: 0001104659-26-066062.txt | 0001104659-26-066062 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
14d ago
|
8-K
| $1.82 $1.96 | ▲ +7.69% | ▲ +6.61% | $1.69 (−7.14%) |
|
May 11, 2026
29d ago
|
Press Release
| $1.82 $1.62 | ▼ −10.99% | ▼ −10.90% | $1.69 (−7.14%) |
|
Apr 28, 2026
6w ago
|
DEFA14A
| $1.76 $1.91 | ▲ +8.52% | ▲ +5.41% | $1.69 (−3.98%) |
|
Mar 26, 2026
10w ago
|
Press Release
| $1.89 $1.85 | ▼ −2.12% | ▼ −3.75% | $1.69 (−10.58%) |
|
Mar 18, 2026
11w ago
|
Press Release
| $1.95 $1.96 | ▲ +0.51% | ▲ +1.23% | $1.69 (−13.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access